Ami Fadia
Stock Analyst at Needham
(2.15)
# 2,627
Out of 4,818 analysts
395
Total ratings
32.29%
Success rate
-4.32%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterates: Hold | n/a | $118.17 | - | 38 | Apr 16, 2025 | |
| NBIX Neurocrine Biosciences | Upgrades: Buy | $138 | $103.25 | +33.66% | 13 | Apr 15, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $210 | $104.19 | +101.55% | 29 | Apr 10, 2025 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Buy | $50 | $28.98 | +72.53% | 35 | Apr 10, 2025 | |
| IMRX Immuneering | Reiterates: Buy | $12 | $1.41 | +751.06% | 15 | Apr 10, 2025 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $5 | $0.71 | +603.63% | 8 | Apr 10, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $30 | $8.70 | +244.83% | 19 | Apr 9, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $19 | $8.33 | +128.09% | 35 | Apr 9, 2025 | |
| MRUS Merus | Reiterates: Buy | $83 | $41.90 | +98.09% | 27 | Apr 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Buy | $59 | $37.56 | +57.08% | 22 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $14.66 | +91.00% | 8 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $133 | $85.93 | +54.78% | 29 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $85 | $36.71 | +131.58% | 10 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $153 | $104.33 | +46.65% | 14 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $4.48 | - | 22 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $7.46 | +328.95% | 19 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $7.64 | - | 19 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $10.41 | +2,973.97% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $25.21 | +197.50% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $1.39 | +1,518.71% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $24.74 | +154.65% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $5 | $2.60 | +92.31% | 2 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $14.29 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.21 | +895.48% | 4 | Jan 3, 2018 |
Biogen
Apr 16, 2025
Reiterates: Hold
Price Target: n/a
Current: $118.17
Upside: -
Neurocrine Biosciences
Apr 15, 2025
Upgrades: Buy
Price Target: $138
Current: $103.25
Upside: +33.66%
Jazz Pharmaceuticals
Apr 10, 2025
Reiterates: Buy
Price Target: $210
Current: $104.19
Upside: +101.55%
Harmony Biosciences Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $50
Current: $28.98
Upside: +72.53%
Immuneering
Apr 10, 2025
Reiterates: Buy
Price Target: $12
Current: $1.41
Upside: +751.06%
Neumora Therapeutics
Apr 10, 2025
Reiterates: Buy
Price Target: $5
Current: $0.71
Upside: +603.63%
Bicycle Therapeutics
Apr 9, 2025
Reiterates: Buy
Price Target: $30
Current: $8.70
Upside: +244.83%
Avadel Pharmaceuticals
Apr 9, 2025
Reiterates: Buy
Price Target: $19
Current: $8.33
Upside: +128.09%
Merus
Apr 9, 2025
Reiterates: Buy
Price Target: $83
Current: $41.90
Upside: +98.09%
Revolution Medicines
Apr 8, 2025
Reiterates: Buy
Price Target: $59
Current: $37.56
Upside: +57.08%
Apr 8, 2025
Reiterates: Buy
Price Target: $28
Current: $14.66
Upside: +91.00%
Apr 8, 2025
Reiterates: Buy
Price Target: $133
Current: $85.93
Upside: +54.78%
Apr 8, 2025
Reiterates: Buy
Price Target: $85
Current: $36.71
Upside: +131.58%
Apr 1, 2025
Reiterates: Buy
Price Target: $153
Current: $104.33
Upside: +46.65%
Feb 26, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.48
Upside: -
Feb 26, 2025
Reiterates: Buy
Price Target: $32
Current: $7.46
Upside: +328.95%
Feb 12, 2025
Reiterates: Hold
Price Target: n/a
Current: $7.64
Upside: -
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $10.41
Upside: +2,973.97%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $25.21
Upside: +197.50%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $1.39
Upside: +1,518.71%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $24.74
Upside: +154.65%
Jan 30, 2019
Downgrades: Market Perform
Price Target: $12 → $5
Current: $2.60
Upside: +92.31%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $14.29
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $2.21
Upside: +895.48%